264 related articles for article (PubMed ID: 29603214)
1. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions.
Calip GS; Patel PR; Adimadhyam S; Xing S; Wu Z; Sweiss K; Schumock GT; Lee TA; Chiu BC
Int J Cancer; 2018 Sep; 143(5):1062-1071. PubMed ID: 29603214
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
[TBL] [Abstract][Full Text] [Related]
4. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
[TBL] [Abstract][Full Text] [Related]
5. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
6. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
7. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
[TBL] [Abstract][Full Text] [Related]
9. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
11. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
12. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
[TBL] [Abstract][Full Text] [Related]
13. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
[TBL] [Abstract][Full Text] [Related]
14. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
15. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
[TBL] [Abstract][Full Text] [Related]
16. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
17. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
18. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
19. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
20. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
